| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | $1,065,034,885 | 17,095,263 | Lin Bioscience International Ltd. | 31 Dec 2024 | |||
| Darwin Global Management, Ltd. | 8.1% | +16% | $479,467,205 | +$65,024,200 | 3,027,704 | +16% | Darwin Global Management, Ltd. | 31 Dec 2025 |
| Lin Yu-Hsin | 7.1% | $142,484,461 | 2,287,070 | Yu-Hsin Lin | 31 Dec 2024 |
As of 31 Dec 2025, 67 institutional investors reported holding 7,179,666 shares of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE). This represents 19% of the company’s total 37,379,062 outstanding shares.
The largest institutional shareholders of BELITE BIO, INC - Ordinary Shares, par value US$0.0001 per share (BLTE) together control 19% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 8.1% | 3,027,704 | 9.9% | $486,915,357 | |
| RTW INVESTMENTS, LP | 1.9% | 715,332 | +129% | 1.1% | $114,424,507 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 558,882 | +2595% | 0.06% | $89,398,765 |
| RA CAPITAL MANAGEMENT, L.P. | 1.2% | 432,484 | -51% | 0.71% | $69,180,141 |
| PERCEPTIVE ADVISORS LLC | 1.1% | 414,239 | +732% | 1.2% | $66,261,670 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1% | 383,091 | +96% | 0.96% | $61,279,236 |
| Point72 Asset Management, L.P. | 0.76% | 284,437 | +9075% | 0.07% | $45,498,543 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.63% | 233,813 | 0.48% | $37,400,727 | |
| MARSHALL WACE, LLP | 0.52% | 192,700 | +2.8% | 0.03% | $30,824,292 |
| UBS Group AG | 0.34% | 128,752 | +1036% | 0% | $20,595,170 |
| MPM BIOIMPACT LLC | 0.23% | 87,760 | 1.6% | $14,038,090 | |
| Holocene Advisors, LP | 0.22% | 84,067 | 0.03% | $13,447,357 | |
| FRED ALGER MANAGEMENT, LLC | 0.21% | 79,394 | 0.05% | $12,699,864 | |
| Western Standard LLC | 0.16% | 60,026 | 4.4% | $9,601,759 | |
| GOLDMAN SACHS GROUP INC | 0.12% | 44,599 | +1103% | 0% | $7,134,056 |
| Soleus Capital Management, L.P. | 0.11% | 40,354 | -81% | 0.27% | $6,455,026 |
| ADAR1 Capital Management, LLC | 0.11% | 39,839 | 0.48% | $6,372,646 | |
| JANE STREET GROUP, LLC | 0.09% | 32,318 | 0.01% | $5,169,587 | |
| MORGAN STANLEY | 0.07% | 28,013 | +436% | 0% | $4,480,960 |
| Squadron Capital Management LLC | 0.07% | 26,000 | 0% | 1.9% | $4,158,960 |
| Quadrature Capital Ltd | 0.07% | 24,832 | +548% | 0.04% | $3,972,127 |
| SUPERSTRING CAPITAL MANAGEMENT LP | 0.07% | 24,703 | 2.1% | $3,951,492 | |
| Affinity Asset Advisors, LLC | 0.05% | 20,000 | 0.23% | $3,199,200 | |
| PFM Health Sciences, LP | 0.05% | 19,823 | 0.32% | $3,170,887 | |
| Woodline Partners LP | 0.05% | 18,041 | 0.01% | $2,885,838 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 7,179,666 | $1,151,084,569 | +$809,573,636 | $159.96 | 67 |
| 2025 Q3 | 2,288,469 | $169,346,585 | +$162,953,207 | $74.00 | 34 |
| 2025 Q2 | 78,139 | $4,508,619 | -$5,101,966 | $57.70 | 18 |
| 2025 Q1 | 149,657 | $9,909,658 | -$8,038,751 | $66.22 | 18 |
| 2024 Q4 | 282,406 | $17,820,740 | +$12,809,959 | $63.10 | 21 |
| 2024 Q3 | 78,699 | $3,689,407 | -$4,872,726 | $46.88 | 15 |
| 2024 Q2 | 186,568 | $8,522,342 | +$5,980,161 | $45.68 | 11 |
| 2024 Q1 | 58,112 | $2,229,758 | -$4,083,463 | $38.37 | 11 |
| 2023 Q4 | 155,109 | $7,095,600 | +$3,531,143 | $45.75 | 17 |
| 2023 Q3 | 99,593 | $3,165,868 | -$26,250,075 | $31.85 | 7 |
| 2023 Q2 | 1,040,502 | $14,866,363 | +$2,374,158 | $14.29 | 6 |
| 2023 Q1 | 850,185 | $25,389,513 | -$211,069 | $29.90 | 8 |
| 2022 Q4 | 857,329 | $25,861,711 | +$22,306,675 | $30.15 | 7 |
| 2022 Q3 | 115,088 | $3,870,578 | +$1,586,624 | $33.76 | 8 |
| 2022 Q2 | 68,935 | $2,146,000 | +$2,146,000 | $31.13 | 6 |